文献速递造血干细胞移植与细胞治疗

COVID-19疫情期间造血干细胞移植与免疫效应细胞治疗:美国癌症中心经验

COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience.
PubMed 文献 · Blood Adv · 2021-01-01

该研究回顾Dana-Farber癌症研究所在COVID-19疫情初期收治的127例细胞治疗患者(62例allo-HSCT、38例auto-HSCT、27例CAR-T),并与疫情前66例allo-HSCT、43例auto-HSCT、33例CAR-T患者对照。尽管供者选择、筛查和供者产品冻存模式有所改变,各组100天总生存、无进展生存、非COVID-19感染率、住院时间、中性粒细胞植入、植入失败、aGVHD及CRS/神经毒性均无差异;HSCT患者在0至100天内无COVID-19感染,1例CAR-T患者在+51天感染并死亡。数据提示在适当防护下细胞治疗可安全开展。

要点

  • 疫情期间细胞治疗患者的100天生存及移植相关并发症与疫情前无差异。
  • HSCT患者在0至100天内无COVID-19感染,仅1例CAR-T患者在+51天感染并死亡。
  • 供者选择、筛查及供者产品冻存模式有所调整,但未影响临床结局。

核心结论

  • 在适当防护措施下,COVID-19疫情期间可安全开展HSCT和CAR-T细胞治疗。

研究设计与样本

  • 疫情初期队列包括62例成人allo-HSCT、38例auto-HSCT和27例CAR-T患者。
  • 对照队列包括66例allo-HSCT、43例auto-HSCT和33例CAR-T患者,HSCT组另设第二对照队列反映季节性感染变化。

主要发现

  • 各组100天总生存、无进展生存、非COVID-19感染率、住院时间、中性粒细胞植入、植入失败均无差异。
  • allo-HSCT患者急性移植物抗宿主病、CAR-T患者细胞因子释放综合征和神经毒性均无差异。
  • HSCT患者在0至100天内无COVID-19感染,1例CAR-T患者在+51天感染COVID-19并死亡。

临床怎么用

  • 细胞治疗中心可在维持适当防护与筛查措施的前提下继续开展HSCT和CAR-T治疗。
  • 供者选择、筛查及供者产品冻存模式的调整未对短期临床结局产生不利影响。

局限性

  • 为单中心回顾性研究,样本量有限,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), identified in late 2019 as the causative agent of COVID-19, was declared a pandemic by the World Health Organization on 11 March 2020. Widespread community transmission in the United States triggered a nationwide shutdown, raising major challenges for administration of hematopoietic stem cell transplant (HSCT) and chimeric antigen receptor (CAR)-T cell therapies, leading many centers to delay or cancel operations. We sought to assess the impact of the COVID-19 pandemic on operations and clinical outcomes for HSCT and CAR-T cellular therapies at the Dana-Farber Cancer Institute by reviewing administration and outcomes in 127 cell therapy patients treated during the initial COVID-19 surge: 62 adult allogeneic HSCT (allo-HSCT), 38 autologous HSCT (auto-HSCT), and 27 CAR-T patients. Outcomes were compared with 66 allo-HSCT, 43 auto-HSCT, and 33 CAR-T patients treated prior to the pandemic. A second control cohort was evaluated for HSCT groups to reflect seasonal variation in infections. Although there were changes in donor selection and screening as well as cryopreservation patterns of donor products, no differences were observed across groups in 100-day overall survival, progression-free survival, rates of non-COVID-19 infections, including hospital length of stay, neutrophil engraftment, graft failure, acute graft-versus-host disease in allo-HSCT patients, or cytokine release syndrome and neurotoxicity in CAR-T patients. No HSCT patients contracted COVID-19 between days 0 and 100. One CAR-T patient contracted COVID-19 at day +51 and died of the disease. Altogether, our data indicate that cellular therapies can be safely administered throughout the ongoing COVID-19 pandemic with appropriate safeguards.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Maurer K, Saucier A, Kim HT, et al. COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Adv. 2021. PMID: 33560397. doi:10.1182/bloodadvances.2020003883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。